Universal Influenza Vaccines 2020

28-30 September 2020, Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size


Due to the current COVID-19 crisis, UIV 2020 has been postponed from 29-30 April – 1 May to 28-30 September 2020.

Join the conversation on Twitter – #UIV2020

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness.

UIV 2020 – this new forum will offer researchers an opportunity to discuss the characteristics of universal influenza vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such universal influenza virus vaccines.

The UIV 2020 Scientific Advisory Panel are calling for abstracts for both oral and poster presentation at the meeting – please see the participation page for abstract submission details.

Scientific Advisory Panel

UIV 2020 Conference Chairman:
Sarah Gilbert (Jenner Institute, University of Oxford, Oxford, UK)

Ted Ross (University of Georgia, Athens, Georgia, USA)
Sean Tucker (VAXART Inc., South San Francisco, California, USA)
John Oxford (Queen Mary University of London, London, UK)
Rob Lambkin-Williams (Virology Consult, London, UK)
Christopher Chadwick (World Health Organization, Geneva, Switzerland)
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)
Othmar Engelhardt (NIBSC, South Mimms, Potters Bar, UK)
Tobias Kamphuis (Janssen Vaccines, Leiden, The Netherlands)
Anke Huckriede (University of Groningen, Groningen, The Netherlands)
Ron Babecoff (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Tamar Ben-Yedidia (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Harry Kleanthous (Gates Foundation, Seattle, Washington, USA)
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)
Emanuele Montomoli (VisMederi Srl, Siena, Italy)
Otfried Kistner (VisMederi, Siena, Italy)
Joanna Waldock (NIBSC, South Mimms, Potters Bar, UK)
Vivek Shinde (Novavax Inc, Rockeville, Maryland, USA)
Yuri Vasiliev (St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)
Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)


UIV 2020 Delegates

Login details will be supplied after you have registered for the event.

UIV 2020 Sponsors

  • The Native Antigen Company
  • VisMederi
  • Vaxart
  • FluConsult
  • Sanofi Pasteur
  • BiondVax
  • Izon Science
  • NanoFCM
  • DNAvaccine.com

UIV 2020 Downloads

UIV 2020 Leaflet

UIV 2020 Mailing List

E-mail Address
What is 3+2-1?